Skip to main content
    P

    Precision BioSciences Inc (DTIL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.28
    -0.28 (-3.77%)

    Market Cap: $288.76M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Precision BioSciences Inc (DTIL) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Precision BioSciences (DTIL) trades at 4.4x sales and 3.9x book value. Its P/S of 4.4x is above its 5-year median of 2.3x. Its forward P/E is 11.8x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E11.8x
    Price to sales4.4x
    Price to book3.9x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S4.4x2.3xN/A
    P/B3.9x1.8xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 7 year ends shown, its P/S ranged from 0.4x in 2024 to 31.5x in 2019.

    Year endPriceP/EP/SP/B
    2025$4.16N/A2.3x0.9x
    2024$3.811.9x0.4x0.5x
    2023$10.96N/A0.9x2.6x
    2022$35.74N/A4.4x2.2x
    2021$222.22N/A3.7x4.9x
    2020$250.45N/A17.9x9.9x
    2019$417.12N/A31.5x5.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DTIL

    What is DTIL's forward P/E ratio?

    Precision BioSciences has a forward P/E ratio of 11.8x.

    Is DTIL stock overvalued?

    GNG's valuation label for DTIL is Overvalued.

    What is DTIL's price to sales ratio?

    Precision BioSciences has a price to sales ratio of 4.4x.